Sarcoma Study of MORAb-004 Utilization: Research and Clinical Evaluation. (SOURCE)

Inclusion Criteria:

- Be at least 18 years of age

- Be surgically sterile or consent to use a medically acceptable method of
contraception throughout the study period

- Have a histologically confirmed diagnosis of mSTS as defined by the 4 specified study
subgrouped

- Have been treated in the metastatic setting with 0 to 2 prior systemic regimens for
mSTS (Systemic treatment regimens given in the neoadjuvant setting and maintenance
therapies will not be considered as regimens in the metastatic setting for the
purposes of this protocol. Prior anthracycline-based regimen is allowable but not
required. Subjects with extra-skeletal small round blue cell sarcomas, including
rhabdomyosarcomas, must have exhausted or be intolerant of standard first line
anthracycline-based chemotherapy.)

- Have measurable disease, as defined by RECIST v 1.1 assess within 2 weeks of study
entry and have radiologically documented disease progression greater than or equal to
a 10% increase in the sum of the longest diameters of target lesions present within 6
months prior to randomization

- Have tumor tissue available for TEM-1 biomarker studies

- Be willing and able to provide written informed consent

Exclusion Criteria:

- Have received more than 2 prior systemic treatment regimens for mSTS

- Have received either gemcitabine or docetaxel in any previous treatment for mSTS
(regardless of the line of treatment)

- Have a diagnosis of primary bone sarcoma of any histological type.

- Have a history of clinically significant heart disease, or clinically significant
arrhythmia on ECG within the past 6 months

- Have a history of allergic reaction to prior monoclonal antibody or biologic agent

- Have received previous treatment with MORAb-004 (anti-TEM-1)

- Have a medical condition with a high risk of bleeding (e.g., a known bleeding
disorder, a coagulopathy, or a tumor that involves the major vessels) or have a
recent (within past 6 months) history of a significant bleeding event

- Have undergone major surgical procedures or open biopsy, have significant traumatic
injury within 30 days prior to the first date of study treatment, or have major
surgical procedures anticipated during the study

- Have a serious non-healing wound, an ulcer (including gastrointestinal), or a bone
fracture